Bleeding disorders:

Indications for OCTAPLAS:

Replacement of multiple coagulation factors with acquired deficiencies due to liver disease, undergoing cardiac surgery, or liver transplant. Plasma exchange in thrombotic thrombocytopenic purpura (TTP).


For IV infusion only after thawing. Administer based on ABO-blood group compatibility. Coagulation factors replacement: initially 10–15mL/kg to increase plasma coagulation factor levels approx. 15–25%; if hemostasis is not achieved, use higher doses. Adjust based on response; monitor aPTT, PT, and/or specific coagulation factors. TTP: usually 1–1.5 plasma volumes (40–60mL/kg) to completely replace plasma volume removed during plasmapheresis.


Not established.


IgA deficiency. Severe Protein S deficiency. Prior hypersensitivity to fresh frozen plasma or plasma-derived products including plasma protein.


Risk of transfusion reactions with ABO blood group mismatches. Risk of hypervolemia with high infusion rates; monitor for signs/symptoms of pulmonary edema or cardiac failure. Hyperfibrinolysis may develop due to low levels of alpha2-antiplasmin; monitor for signs of excessive bleeding in liver transplantation. Monitor for thrombosis. Risk of citrate toxicity; use max infusion rate: 0.020–0.025mmol citrate/kg/min (eg, Octaplas <1mL/kg/min). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.

Pharmacologic Class:

Pooled plasma (human).


Avoid injecting calcium-containing drugs in same IV line.

Adverse Reactions:

Pruritus, urticaria, nausea, headache, paresthesia; anaphylactic shock, citrate toxicity, severe hypotension.

How Supplied: